Compare UXIN & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UXIN | ARMP |
|---|---|---|
| Founded | 2011 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.6M | 199.7M |
| IPO Year | 2018 | 1996 |
| Metric | UXIN | ARMP |
|---|---|---|
| Price | $0.81 | $3.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | ★ 124.5K | 83.8K |
| Earning Date | 12-17-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $59.68 | N/A |
| Revenue Next Year | $71.25 | N/A |
| P/E Ratio | $4.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $2.75 |
| 52 Week High | $4.18 | $14.98 |
| Indicator | UXIN | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 55.86 |
| Support Level | N/A | $3.38 |
| Resistance Level | $1.02 | $3.96 |
| Average True Range (ATR) | 0.10 | 0.37 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 46.14 | 93.33 |
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates a car retailer, pioneering industry transformation with production, new retail experiences, and digital empowerment in China. With its inventory-owning model, it provides customers a comprehensive transaction solution that encompasses the entire value chain, ranging from used-car acquisition, inspection, and reconditioning, warehousing, as well as pre-sales and after-sales services. The group offers high-quality and value-for-money used cars as well as superior full suites of services to customers through a reliable, one-stop, and hassle-free transaction experience. It derives revenues from retail vehicle sales, wholesale vehicle sales, and other businesses. The Group generates its revenues in China.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.